Valneva SE

VALN · NYSE

$5.26−$0.10 (−1.87%)TodayMarket closed · Oct 23, 7:55 PM ET

Prev close $5.36

VALN analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 9, 2026

Bull case

Valneva SE has demonstrated a positive outlook with its Lyme vaccine candidate VLA15, showing strong immune responses after a third yearly booster in both adults and children, indicating the potential for successful commercialization. The company has also modestly adjusted its assumptions for commercial uptake of VLA15 in Europe, aligning them more closely with the positive expectations set in the U.S., which could enhance revenue projections. Despite facing regulatory challenges with the Ixchiq vaccine, the overall optimistic developments in its portfolio, particularly with VLA15, suggest a favorable trajectory for future financial performance.

Bear case

Valneva SE faces significant risks that adversely impact its financial outlook, including potential clinical and regulatory setbacks, increased competition from alternative vaccine programs, and lower-than-expected product sales. Recent safety concerns regarding its vaccine IXCHIQ have raised doubts about its competitiveness against rival products, such as Bavarian Nordic's chikungunya vaccine, even though Valneva claims superior long-term protection. Additionally, the suspension of all US IXCHIQ sales from financial models and expectations of limited commercial uptake in Europe due to safety issues further contribute to a negative outlook for the company's future revenue generation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.